Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21624691 | 1.00 | LMNA (0.49) | LMNAKMT2APOLBCNR2KDM1A | |
| SCHEMBL21624693 | 1.00 | LMNA (0.49) | LMNAKMT2APOLBCNR2KDM1A | |
| SCHEMBL21624779 | 0.92 | LMNA (0.55) | LMNAKMT2APOLBCNR2MEN1 | |
| SCHEMBL23387364 | 0.89 | LMNA (0.50) | LMNAKMT2APOLBCNR2MEN1 | |
| SCHEMBL15054874 | 0.82 | SIGMAR1 (0.52) | LMNAKMT2APOLBKDM1AMEN1 | |
| SCHEMBL34468348 | 0.82 | SIGMAR1 (0.52) | LMNAKMT2APOLBKDM1AMEN1 | |
| SCHEMBL30718482 | 0.81 | EPHX2 (0.62) | KMT2AKDM1AMEN1EPHX2ALDH1A1 | |
| SCHEMBL15055182 | 0.81 | EPHX2 (0.62) | KMT2AKDM1AMEN1EPHX2ALDH1A1 | |
| SCHEMBL34468338 | 0.81 | EPHX2 (0.62) | KMT2AKDM1AMEN1EPHX2ALDH1A1 | |
| SCHEMBL13883884 | 0.81 | HDAC4 (0.50) | LMNAKMT2AMEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321092-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2023-10-12 | — | — | US | disclosed |
| US-11547709-B2 | Methods of treating disorders associated with castor | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210023081-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2021-01-28 | — | — | US | disclosed |
| US-20190300499-A1 | SMALL MOLECULE MODULATORS OF PANTOTHENATE KINASES | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2019-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321092-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | HMGCR, GCDH, CYP11A1 | LMNA 1621/4885KMT2A 1296/4885POLB 1599/4885 |
| US-11547709-B2 | Methods of treating disorders associated with castor | HMGCR, GCDH, CYP11A1 | LMNA 1621/4885KMT2A 1296/4885POLB 1599/4885 |
| US-20210023081-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | HMGCR, GCDH, CYP11A1 | LMNA 1621/4885KMT2A 1296/4885POLB 1599/4885 |
| US-20190300499-A1 | SMALL MOLECULE MODULATORS OF PANTOTHENATE KINASES | PANK2, PANK1, PANK3 | LMNA 1792/4885KMT2A 1775/4885POLB 1901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.